Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 17266884)

  • 1. [Overexpression and prognostic value of p53 and HER2/neu proteins in benign ovarian tissue and in ovarian cancer].
    Coronado Martín PJ; Fasero Laiz M; García Santos J; Ramírez Mena M; Vidart Aragón JA
    Med Clin (Barc); 2007 Jan; 128(1):1-6. PubMed ID: 17266884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor histology and stage but not p53, Her2-neu or cathepsin-D expression are independent prognostic factors in breast cancer patients.
    Korkolis DP; Tsoli E; Fouskakis D; Yiotis J; Koullias GJ; Giannopoulos D; Papalambros E; Nikiteas NI; Spiliopoulou CA; Patsouris E; Asimacopoulos P; Gorgoulis VG
    Anticancer Res; 2004; 24(3b):2061-8. PubMed ID: 15274401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic Value of KIF2A and HER2-Neu Overexpression in Patients With Epithelial Ovarian Cancer.
    Wang D; Zhu H; Ye Q; Wang C; Xu Y
    Medicine (Baltimore); 2016 Feb; 95(8):e2803. PubMed ID: 26937910
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p53 and HER-2/neu overexpression in ovarian borderline tumors.
    Eltabbakh GH; Belinson JL; Kennedy AW; Biscotti CV; Casey G; Tubbs RR
    Gynecol Oncol; 1997 May; 65(2):218-24. PubMed ID: 9159328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Relationship between expressions of p53, c-erbB2 genes, proliferating cell nuclear antigen and prognosis of patients with ovarian epithelial carcinoma].
    Li JD; Li MD; Li YF; Huang X; Liu JH; Liu FY; Zhang CQ
    Ai Zheng; 2002 Mar; 21(3):292-6. PubMed ID: 12451998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. P53 overexpression predicts endometrial carcinoma recurrence better than HER-2/neu overexpression.
    Coronado PJ; Vidart JA; Lopez-asenjo JA; Fasero M; Furio-bacete V; Magrina J; Escudero M
    Eur J Obstet Gynecol Reprod Biol; 2001 Sep; 98(1):103-8. PubMed ID: 11516808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of p53 and HER2/Neu in Kenyan Women With Primary Ovarian Carcinoma.
    Mutuiri AP; Nzioka A; Busarla SV; Sayed S; Moloo Z
    Int J Gynecol Pathol; 2016 Nov; 35(6):537-543. PubMed ID: 26825003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Significance of cell cycle regulatory proteins as malignant and prognostic biomarkers in ovarian epithelial tumors.
    Lee YH; Heo JH; Kim TH; Kang H; Kim G; Kim J; Cho SH; An HJ
    Int J Gynecol Pathol; 2011 May; 30(3):205-17. PubMed ID: 21464733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two types of primary mucinous ovarian tumors can be distinguished based on their origin.
    Simons M; Simmer F; Bulten J; Ligtenberg MJ; Hollema H; van Vliet S; de Voer RM; Kamping EJ; van Essen DF; Ylstra B; Schwartz LE; Wang Y; Massuger LF; Nagtegaal ID; Kurman RJ
    Mod Pathol; 2020 Apr; 33(4):722-733. PubMed ID: 31695154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The N-terminally truncated p53 isoform Δ40p53 influences prognosis in mucinous ovarian cancer.
    Hofstetter G; Berger A; Berger R; Zorić A; Braicu EI; Reimer D; Fiegl H; Marth C; Zeimet AG; Ulmer H; Moll U; Zeillinger R; Concin N
    Int J Gynecol Cancer; 2012 Mar; 22(3):372-9. PubMed ID: 22246403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multivariate analyses of DNA index, p62c-myc, and clinicopathological status of patients with ovarian cancer.
    Curling M; Stenning S; Hudson CN; Watson JV
    J Clin Pathol; 1998 Jun; 51(6):455-61. PubMed ID: 9771445
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of cyclooxygenase-2 expression on tumor vascularity in advanced stage ovarian serous carcinoma.
    Ali-Fehmi R; Che M; Khalifeh I; Malone JM; Morris R; Lawrence WD; Munkarah AR
    Cancer; 2003 Oct; 98(7):1423-9. PubMed ID: 14508829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Misregulation of polo-like protein kinase 1, P53 and P21WAF1 in epithelial ovarian cancer suggests poor prognosis.
    Zhang R; Shi H; Ren F; Liu H; Zhang M; Deng Y; Li X
    Oncol Rep; 2015 Mar; 33(3):1235-42. PubMed ID: 25592872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Expression of hSef and FGF-2 in epithelial ovarian tumor].
    Feng QL; Shi HR; Qiao LJ; Zhao J
    Zhonghua Zhong Liu Za Zhi; 2011 Oct; 33(10):770-4. PubMed ID: 22335910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Value of P-glycoprotein, glutathione S-transferase pi, c-erbB-2, and p53 as prognostic factors in ovarian carcinomas.
    van der Zee AG; Hollema H; Suurmeijer AJ; Krans M; Sluiter WJ; Willemse PH; Aalders JG; de Vries EG
    J Clin Oncol; 1995 Jan; 13(1):70-8. PubMed ID: 7799045
    [TBL] [Abstract][Full Text] [Related]  

  • 16. c-erbB-2, p53, and nm23 proteins as prognostic factors in patients with epithelial ovarian carcinoma.
    Tomić S; Ilić Forko J; Babić D; Sundov D; Kuret S; Andelinović S
    Croat Med J; 2003 Aug; 44(4):429-34. PubMed ID: 12950146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A case-matched molecular comparison of extraovarian versus primary ovarian adenocarcinoma.
    Kowalski LD; Kanbour AI; Price FV; Finkelstein SD; Christopherson WA; Seski JC; Naus GJ; Burnham JA; Kanbour-Shakir A; Edwards RP
    Cancer; 1997 Apr; 79(8):1587-94. PubMed ID: 9118043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Heterogeneity of epithelial ovarian carcinomas and their clinical significance].
    Noske A
    Praxis (Bern 1994); 2014 Jan; 103(3):155-9. PubMed ID: 24468455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence and significance of HER-2/neu expression in early epithelial ovarian cancer.
    Rubin SC; Finstad CL; Federici MG; Scheiner L; Lloyd KO; Hoskins WJ
    Cancer; 1994 Mar; 73(5):1456-9. PubMed ID: 7906607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
    Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
    J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.